- Conditions
- Prostate Cancer
- Interventions
- REGN5678, Cemiplimab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 925
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor
- Interventions
- sunitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 15
- States / cities
- Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more
- Conditions
- Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
- Interventions
- BKM120
- Drug
- Lead sponsor
- Andrew J. Armstrong, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Portland, Oregon • Seattle, Washington
- Conditions
- Prostate Cancer, Prostatic Neoplasms
- Interventions
- Cabazitaxel plus bavituximab
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Interventions
- XL102, Fulvestrant, Abiraterone, Prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
- Conditions
- Prostate Cancer
- Interventions
- CEP-701
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Metastatic Hormone Refractory Prostate Cancer
- Interventions
- Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Prostate Cancer
- Interventions
- CXCR2 as a biomarker
- Diagnostic Test
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Ann Arbor, Michigan • Durham, North Carolina
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- Investigational Agent Administration
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Metastatic Progressive Castration-resistant Prostate Cancer, Metastatic Progressive Breast Cancer
- Interventions
- Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Urologic Neoplasms, Prostate Cancer, Prostate Cancer Metastatic Disease
- Interventions
- Docetaxel, Biosyn, Prednisone
- Drug
- Lead sponsor
- Sandy Srinivas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hormone Refractory Prostate Cancer
- Interventions
- Docetaxel, TroVax
- Drug
- Lead sponsor
- Oxford BioMedica
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 7
- States / cities
- San Bernardino, California • Stanford, California • Chicago, Illinois + 4 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Erdafitinib
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
- Interventions
- Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Houston, Texas
- Conditions
- Prostate Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
- Interventions
- Abiraterone Acetate, Prednisone\Prednisolone
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 154 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- PACE with Cabazitaxel (15 mg/m2), PACE with Cabazitaxel (20 mg/m2)
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Inavolisib, Enzalutamide, Abiraterone, Docetaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- San Francisco, California • Iowa City, Iowa • The Bronx, New York + 2 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Apalutamide, Abiraterone acetate, Docetaxel, Prednisone
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • New York, New York
- Conditions
- Prostate Carcinoma Metastatic to the Bone
- Interventions
- Enzalutamide, Radium ra 223 dichloride
- Drug · Radiation
- Lead sponsor
- Carolina Research Professionals, LLC
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Towson, Maryland • Syracuse, New York • Myrtle Beach, South Carolina + 1 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Exicorilant, Enzalutamide, Placebo
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more
- Conditions
- Castration-resistant Prostate Cancer, CRPC
- Interventions
- VT-464: given orally once daily in 28 day cycles
- Drug
- Lead sponsor
- Innocrin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Omaha, Nebraska • Durham, North Carolina + 2 more
- Conditions
- PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
- Interventions
- AMO959, AAA617, Enzalutamide, Abiraterone
- Drug · Radiation
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- El Paso, Texas • Murray, Utah
- Conditions
- Prostate Cancer
- Interventions
- Irofulven, Prednisone, Mitoxantrone, Capecitabine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 29
- States / cities
- Hot Springs, Arkansas • Jonesboro, Arkansas • Greenbrae, California + 26 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- SX-682, Enzalutamide
- Drug
- Lead sponsor
- Syntrix Biosystems, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Ann Arbor, Michigan + 3 more